Editorial comment on: development and external validation of a model to predict overall survival in patients with resected gallbladder cancer  

作　　者：Mairéad G.McNamara 

机构地区：[1]Division of Cancer Sciences,University of Manchester&The Christie NHS Foundation Trust,Manchester,UK

出　　处：《Hepatobiliary Surgery and Nutrition》2022年第1期147-149,共3页肝胆外科与营养（英文）

摘　　要：The incidence of biliary tract cancer(BTC)(1),including gallbladder cancer(GBC)(2),is increasing.Potentially curative surgery is possible in only approximately 20%,and adjuvant capecitabine,versus observation after resection,has been reported to improve survival in a prespecified sensitivity and per-protocol analyses of the phase 3 randomised trial BILCAP(capecitabine compared with observation in resected BTC)(adjusting for minimisation factors,nodal status,grade,and gender)(3,4).The prognosis for patients with advanced BTC is poor;the median overall survival(OS)for patients receiving standard of care cisplatin/gemcitabine in the first-line setting was 11.7 months in the Advanced Biliary Cancer-02(ABC-02)study(5).There has been no alteration in the established choice of first-line systemic treatment for advanced BTC for over a decade.However,a recent press release announced that the phase 3 randomised study of durvalumab in combination with cisplatin/gemcitabine versus placebo with cisplatin/gemcitabine as a first-line treatment for patients with advanced BTC(TOPAZ-1)had met its primary endpoint of OS at the interim analysis;detailed results are awaited(NCT03875235).

关 键 词：PATIENTS GALLBLADDER CANCER 

分 类 号：R73[医药卫生—肿瘤]